GlobalBio Diagnostics

GlobalBio is a Cambridge-based biotechnology company focused on developing advanced rapid diagnostic tools for infectious diseases. The company's core technology is a high-sensitivity lateral flow assay platform designed to provide laboratory-quality results at the point of care. Their flagship product, the GlobalBio COVID-19 Antigen Rapid Test, received Emergency Use Authorization from the FDA and is utilized in various clinical and community settings. GlobalBio is currently expanding its portfolio to include multiplex tests for respiratory viruses, including combined COVID-19 and Influenza A/B panels. By leveraging innovative biochemical engineering, the company aims to make rapid, accurate testing more accessible globally.